{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:01:11Z","timestamp":1783814471126,"version":"3.55.0"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) affect \u224890% of individuals with TSC and significantly reduce their quality of life (QoL). However, there are limited studies assessing pharmacotherapy for TAND. A plant-derived highly purified pharmaceutical formulation of cannabidiol (CBD; Epidiolex<jats:sup>\u00ae<\/jats:sup>\/Epidyolex<jats:sup>\u00ae<\/jats:sup> oral solution) is approved for seizures associated with TSC. Anecdotal evidence also suggests psychiatric, neuropsychological, and behavioral benefits of CBD. EpiCom (<jats:bold>Epi<\/jats:bold>lepsy <jats:bold>Com<\/jats:bold>orbidities; NCT05864846; EU-CT, 2023-507426-17), a multicenter, open-label, phase 3b\/4 study, with hybrid decentralized approach, was designed in collaboration with patient advisory groups and healthcare professionals to evaluate behavioral and other outcomes following adjunctive CBD treatment in individuals with TSC-associated seizures. EpiCom will enroll participants, aged 1\u201365 years (United States [US]) or 2\u201365 years (United Kingdom [UK], Canada, and Poland), who are starting CBD for seizures and have moderate\/severe behavioral challenges according to the Caregiver Global Impression of Severity scale at screening. Participants will receive CBD (up to 25\u2009mg\/kg\/d based on individual response and tolerability) in addition to their standard of care (SoC) for 26 weeks, after which participants may choose to continue CBD with SoC or SoC alone for an additional 26 weeks. Key efficacy endpoints include change from baseline on the Aberrant Behavior Checklist (e.g., irritability subscale) and the most problematic behavior on the TAND-Self-Report, Quantified Checklist. Changes in executive function, sleep, QoL, family functioning, seizure outcomes (severity, responder rates, seizure-free days), retention rate, and safety will be evaluated. The trial will enroll \u224875 participants at \u224820 sites across the US, the UK, Canada, and Poland. EpiCom will assess the changes in behavioral and other outcomes associated with TAND and seizure outcomes, including overall symptom severity and treatment retention, following adjunctive CBD treatment in individuals with TSC-associated seizures. The results will inform future studies evaluating pharmacotherapy for behavioral outcomes in similar populations.<\/jats:p>","DOI":"10.1371\/journal.pone.0324648","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:32:08Z","timestamp":1749749528000},"page":"e0324648","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protocol for EpiCom: A phase 3b\/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8149-8645","authenticated-orcid":true,"given":"Agnies M.","family":"van Eeghen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debopam","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-2824","authenticated-orcid":true,"given":"Anna C.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2499-1775","authenticated-orcid":true,"given":"Lisa","family":"Moore-Ramdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrus J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"pone.0324648.ref001","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2020.01028","article-title":"Tuberous sclerosis complex as disease model for investigating mTOR-related gliopathy during epileptogenesis","volume":"11","author":"TS Zimmer","year":"2020","journal-title":"Front Neurol"},{"key":"pone.0324648.ref002","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1038\/ncomms15816","article-title":"The genomic landscape of tuberous sclerosis complex","volume":"8","author":"KR Martin","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0324648.ref003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","article-title":"TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients","volume":"12","author":"JC Kingswood","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"pone.0324648.ref004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s11689-022-09423-3","article-title":"The research landscape of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)-a comprehensive scoping review","volume":"14","author":"S Vanclooster","year":"2022","journal-title":"J Neurodev Disord"},{"issue":"1","key":"pone.0324648.ref005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13023-019-1258-3","article-title":"A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC)","volume":"15","author":"JP Z\u00f6llner","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"pone.0324648.ref006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s11689-023-09500-1","article-title":"International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)","volume":"15","author":"PJ de Vries","year":"2023","journal-title":"J Neurodev Disord"},{"issue":"10","key":"pone.0324648.ref007","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2788.2009.01208.x","article-title":"From mtor to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis","volume":"53","author":"D Ehninger","year":"2009","journal-title":"J Intellect Disabil Res"},{"issue":"8","key":"pone.0324648.ref008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2007.06.003","article-title":"The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment","volume":"13","author":"PJ de Vries","year":"2007","journal-title":"Trends Mol Med"},{"key":"pone.0324648.ref009","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yebeh.2017.02.007","article-title":"Influence of seizures on early development in tuberous sclerosis complex","volume":"70","author":"JK Capal","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"11","key":"pone.0324648.ref010","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1017\/S0033291715000264","article-title":"Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study","volume":"45","author":"PF Bolton","year":"2015","journal-title":"Psychol Med"},{"key":"pone.0324648.ref011","doi-asserted-by":"crossref","first-page":"106844","DOI":"10.1016\/j.yebeh.2019.106844","article-title":"Language predictors of autism spectrum disorder in young children with tuberous sclerosis complex","volume":"103","author":"A Schoenberger","year":"2020","journal-title":"Epilepsy Behav"},{"key":"pone.0324648.ref012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2019.12.016","article-title":"Epilepsy and neurodevelopmental comorbidities in tuberous sclerosis complex: a natural history study","volume":"106","author":"A Gupta","year":"2020","journal-title":"Pediatr Neurol"},{"key":"pone.0324648.ref013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"H Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"pone.0324648.ref014","author":"The U.S. Food and Drug Administration","year":"2023"},{"key":"pone.0324648.ref015","author":"European Medicines Agency","year":"2023"},{"issue":"10","key":"pone.0324648.ref016","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"EJ Hess","year":"2016","journal-title":"Epilepsia"},{"key":"pone.0324648.ref017","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/08830738231185241","article-title":"Caregivers\u2019 perspectives on the impact of cannabidiol (CBD) treatment for Dravet and Lennox-Gastaut syndromes: a multinational qualitative study","volume":"38","author":"J Marshall","year":"2023","journal-title":"J Child Neurol"},{"issue":"4","key":"pone.0324648.ref018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"DA Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"pone.0324648.ref019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2023.07.001","article-title":"Development and feasibility of the self-report quantified tuberous sclerosis complex-associated neuropsychiatric disorders checklist (TAND-SQ)","volume":"147","author":"TM Heunis","year":"2023","journal-title":"Pediatr Neurol"},{"issue":"1","key":"pone.0324648.ref020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the tand checklist","volume":"52","author":"P de Vries","year":"2015","journal-title":"Pediatr Neurol"},{"key":"pone.0324648.ref021","doi-asserted-by":"crossref","first-page":"834628","DOI":"10.3389\/fpsyt.2022.834628","article-title":"Empowering families through technology: a mobile-health project to reduce the TAND identification and treatment gap (TANDem)","volume":"13","author":"T-M Heunis","year":"2022","journal-title":"Front Psychiatry"},{"issue":"1","key":"pone.0324648.ref022","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13023-021-02076-w","article-title":"Multivariate data analysis identifies natural clusters of Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND)","volume":"16","author":"PJ de Vries","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"pone.0324648.ref023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12916-023-03012-4","article-title":"Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM","volume":"21","author":"AR M\u00fcller","year":"2023","journal-title":"BMC Med"},{"issue":"2","key":"pone.0324648.ref024","first-page":"129","article-title":"Using patient perspectives to inform better clinical trial design and conduct: current trends and future directions","volume":"37","author":"SD Faulkner","year":"2023","journal-title":"Pharmaceut Med"},{"issue":"4","key":"pone.0324648.ref025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"International Tuberous Sclerosis Complex Consensus Group","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"7","key":"pone.0324648.ref026","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","article-title":"Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment","volume":"42","author":"SM Sansone","year":"2012","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"pone.0324648.ref027","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ridd.2013.01.002","article-title":"An evaluation of the Aberrant Behavior Checklist for children under age 5","volume":"34","author":"JD Schmidt","year":"2013","journal-title":"Res Dev Disabil"},{"issue":"5","key":"pone.0324648.ref028","first-page":"485","article-title":"The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects","volume":"89","author":"MG Aman","year":"1985","journal-title":"Am J Ment Defic"},{"issue":"4","key":"pone.0324648.ref029","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ajmg.a.30622","article-title":"Down syndrome and comorbid autism-spectrum disorder: characterization using the aberrant behavior checklist","volume":"134","author":"GT Capone","year":"2005","journal-title":"Am J Med Genet A"},{"issue":"4","key":"pone.0324648.ref030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10803-012-1624-7","article-title":"A pilot study of parent training in young children with autism spectrum disorders and disruptive behavior","volume":"43","author":"K Bearss","year":"2013","journal-title":"J Autism Dev Disord"},{"key":"pone.0324648.ref031","doi-asserted-by":"crossref","first-page":"545445","DOI":"10.3389\/fpsyt.2020.545445","article-title":"Reliability and validity of the simplified Chinese version of the Aberrant Behavior Checklist in Chinese autism population","volume":"11","author":"S Kat","year":"2020","journal-title":"Front Psychiatry"},{"issue":"6","key":"pone.0324648.ref032","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"R Owen","year":"2009","journal-title":"Pediatrics"},{"key":"pone.0324648.ref033","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajp.2017.04.023","article-title":"Incremental validity of the Child Behavior Checklist (CBCL) and the Strengths and Difficulties Questionnaire (SDQ) in Vietnam","volume":"29","author":"H-M Dang","year":"2017","journal-title":"Asian J Psychiatr"},{"issue":"2","key":"pone.0324648.ref034","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/dmcn.14055","article-title":"Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study","volume":"61","author":"I Toldo","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"pone.0324648.ref035","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/gps.2459","article-title":"Broad spectrum assessment of psychopathology and adaptive functioning with the Older Adult Behavior Checklist: a validation and diagnostic discrimination study","volume":"25","author":"BD Brigidi","year":"2010","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"pone.0324648.ref036","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.3390\/ijerph18126352","article-title":"The application of the adult self-report and the adult behavior checklist form to Chinese adults: syndrome structure, inter-informant agreement, and cultural comparison","volume":"18","author":"J Liu","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0324648.ref037","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13034-019-0291-2","article-title":"International findings with the Achenbach System of Empirically Based Assessment (ASEBA): applications to clinical services, research, and training","volume":"13","author":"TM Achenbach","year":"2019","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"11","key":"pone.0324648.ref038","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"D Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"pone.0324648.ref039","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yebeh.2017.04.047","article-title":"Adults with an epilepsy history fare significantly worse on positive mental and physical health than adults with other common chronic conditions-Estimates from the 2010 National Health Interview Survey and Patient Reported Outcome Measurement System (PROMIS) Global Health Scale","volume":"72","author":"R Kobau","year":"2017","journal-title":"Epilepsy Behav"},{"key":"pone.0324648.ref040","author":"National Institutes of Health.","year":"2023"},{"key":"pone.0324648.ref041","first-page":"227","article-title":"Behavior rating inventory of executive function, 2nd ed","volume":"3","author":"P Dodzik","year":"2017","journal-title":"J Pediatr Neuropsychol"},{"issue":"11","key":"pone.0324648.ref042","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1528-1167.2006.00816.x","article-title":"Executive dysfunction is a significant predictor of poor quality of life in children with epilepsy","volume":"47","author":"EMS Sherman","year":"2006","journal-title":"Epilepsia"},{"issue":"5","key":"pone.0324648.ref043","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/09297041003679344","article-title":"Behavior Rating Inventory of Executive Function \u2013 Preschool Version (BRIEF-P): test review and clinical guidelines for use","volume":"16","author":"EMS Sherman","year":"2010","journal-title":"Child Neuropsychol"},{"issue":"1","key":"pone.0324648.ref044","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0829573518797762","article-title":"Test Review: Behavior Rating Inventory of Executive Function\u00ae, Second Edition (BRIEF\u00ae2) by Gioia, G. A., Isquith, P. K., Guy, S. C., & Kenworthy, L","volume":"34","author":"NK Hendrickson","year":"2018","journal-title":"Canadian Journal of School Psychology"},{"issue":"5","key":"pone.0324648.ref045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/arclin\/act031","article-title":"Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function-Adult version in healthy adults and application to attention-deficit\/hyperactivity disorder","volume":"28","author":"RM Roth","year":"2013","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"pone.0324648.ref046","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40101-017-0151-9","article-title":"Reliability and validity of a brief sleep questionnaire for children in Japan","volume":"36","author":"M Okada","year":"2017","journal-title":"J Physiol Anthropol"},{"issue":"8","key":"pone.0324648.ref047","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/sleep\/23.8.1d","article-title":"The Children\u2019s Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children","volume":"23","author":"JA Owens","year":"2000","journal-title":"Sleep"},{"issue":"7","key":"pone.0324648.ref048","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jpepsy\/jsq119","article-title":"Evidence-based review of subjective pediatric sleep measures","volume":"36","author":"AS Lewandowski","year":"2011","journal-title":"J Pediatr Psychol"},{"key":"pone.0324648.ref049","doi-asserted-by":"crossref","first-page":"101466","DOI":"10.1016\/j.smrv.2021.101466","article-title":"Sleep quality and daytime sleepiness in epilepsy: systematic review and meta-analysis of 25 studies including 8,196 individuals","volume":"57","author":"M Bergmann","year":"2021","journal-title":"Sleep Med Rev"},{"issue":"2","key":"pone.0324648.ref050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"DJ Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"pone.0324648.ref051","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.smrv.2015.01.009","article-title":"The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis","volume":"25","author":"T Mollayeva","year":"2016","journal-title":"Sleep Med Rev"},{"issue":"2","key":"pone.0324648.ref052","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"JW Varni","year":"1999","journal-title":"Med Care"},{"issue":"8","key":"pone.0324648.ref053","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL\u2122 4.0: reliability and validity of the Pediatric Quality of Life Inventory\u2122 Version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"JW Varni","year":"2001","journal-title":"Med Care"},{"key":"pone.0324648.ref054","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-7525-2-55","article-title":"The PedsQL Family Impact Module: preliminary reliability and validity","volume":"2","author":"JW Varni","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"pone.0324648.ref055","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s11136-013-0422-9","article-title":"Utility of the PedsQL\u2122 family impact module: assessing the psychometric properties in a community sample","volume":"22","author":"GR Medrano","year":"2013","journal-title":"Qual Life Res"},{"issue":"7","key":"pone.0324648.ref056","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"J Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"pone.0324648.ref057","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12955-021-01813-w","article-title":"Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy","volume":"19","author":"H Staunton","year":"2021","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"pone.0324648.ref058","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1067\/mob.2003.379","article-title":"Validation of two global impression questionnaires for incontinence","volume":"189","author":"I Yalcin","year":"2003","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"pone.0324648.ref059","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11032-023-01422-z","article-title":"Mining novel genomic regions and candidate genes of heading and flowering dates in bread wheat by SNP- and haplotype-based GWAS","volume":"43","author":"P Qiao","year":"2023","journal-title":"Mol Breed"},{"issue":"7","key":"pone.0324648.ref060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jval.2021.01.005","article-title":"Use of patient and investigator global impression scales: a review of Food and Drug Administration-Approved Labeling, 2009 to 2019","volume":"24","author":"A Gnanasakthy","year":"2021","journal-title":"Value Health"},{"key":"pone.0324648.ref061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.04.1262","article-title":"PMU101 most bothersome symptom measurement strategies: considerations for regulated clinical trials","volume":"22","author":"I Mazar","year":"2019","journal-title":"Value in Health"},{"issue":"10","key":"pone.0324648.ref062","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1089\/jpm.2018.0622","article-title":"Symptom assessment in patients with advanced cancer: are the most severe symptoms the most bothersome?","volume":"22","author":"B Li","year":"2019","journal-title":"J Palliat Med"},{"key":"pone.0324648.ref063","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"pone.0324648.ref064","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","article-title":"Mediation analysis: a practitioner\u2019s guide","volume":"37","author":"TJ VanderWeele","year":"2016","journal-title":"Annu Rev Public Health"},{"key":"pone.0324648.ref065","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"pone.0324648.ref066","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3389\/fneur.2019.01116","article-title":"Tuberous sclerosis complex (TSC): expert recommendations for provision of coordinated care","volume":"10","author":"NMP Annear","year":"2019","journal-title":"Front Neurol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T17:32:20Z","timestamp":1749749540000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324648"}},"subtitle":[],"editor":[{"given":"Ayataka","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324648","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}